Big Ten study tests pembrolizumab and goserelin in advanced AR+ salivary gland cancer

A Big Ten Cancer Research Consortium phase II study for adults with advanced androgen receptor-positive (AR+) salivary gland cancer will test combining the PD-1 inhibitor pembrolizumab and the androgen deprivation therapy goserelin. This study is open for accrual at the University of Illinois Cancer Center, along with other Big Ten institutions. Researchers hope to learn whether this combination is better, the same, or worse than the usual approach to treating this type of cancer.

Learn more here

Share on facebook
Share on twitter

Translate »